A Randomized, Placebo-controlled, Double-blind Phase II Study Evaluating if Glucophage Can Avoid Liver Injury Due to Chemotherapy Associated Steatosis

ABSTRACT: This multicenter randomized, placebo-controlled phase II study will enroll 132 first-line palliative treated subjects with metastatic KRAS wild type CRC. Subjects with histologically confirmed, KRAS wild-type CRC without previous chemo-therapy for metastatic disease will be screened for this study. Approximately 10 sites in Austria will participate in the study. Subjects will be randomized in a ratio of 1:1 into two groups.

DISEASE(S): Fatty Liver,Steatohepatitis,Colorectal Cancer,First-line Palliative Treated, Kras-wild-type, Metastatic Colorectal Cancer,Colorectal Neoplasms

PROVIDER: 2119641 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR